Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo

Experimental Eye Research

Volumn 85, Issue 1, 2007, Pages 44-53

  Szurman, Peter ^a   Sierra, Ana ^a   Kaczmarek, Radoslaw ^a   Jaissle, Gesine B ^a   Wallenfels Thilo, Barbara ^a   Grisanti, Salvatore ^a   Lüke, Matthias ^a   Bartz Schmidt, Karl U ^a   Spitzer, Martin S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

epiretinal deposit; intravitreal; ocular cell culture; retinal cytotoxicity; triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MEMBRANE FILTER; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; RETINA CELL; RETINA GANGLION CELL; VITRECTOMY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BASEMENT MEMBRANE; CELL DEATH; CELL LINE; CELL LINE, TRANSFORMED; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS; PARTICLE SIZE; PIGMENT EPITHELIUM OF EYE; RATS; RETINAL GANGLION CELLS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 34347329165     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.03.003     Document Type: Article

References (29)

1. Behl C.R., Block L.H., and Borke M.L. Aqueous solubility of 14C-triamcinolone acetonide. J. Pharm. Sci. 65 (1976) 429-430
2. D'Amico D.J., and VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113 (2006) 1001.e1-1001.e6
3. Danis R.P., Ciulla T.A., Pratt L.M., and Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
4. Dunn K.C., Aotaki-Keen A.E., Putkey F.R., and Hjelmeland L.M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye. Res. 62 (1996) 155-169
5. Fraser E.A., Cheema R.A., and Roberts M.A. Triamcinolone acetonide-assisted peeling of retinal internal limiting membrane for macular surgery. Retina 23 (2003) 883-884
6. Gupta D., and Ho P.S. Some formal aspects of diffusion. In: Gupta D., and Ho P.S. (Eds). Diffusion Phenomena in Thin Films and Microelectronic Materials (1988), Noyes Publications, Park Ridge, New Jersey
7. Gupta V.D. Stability of triamcinolone acetonide solutions as determined by high-performance liquid chromatography. J. Pharm. Sci. 72 (1983) 1453-1456
8. Hernaez-Ortega M.C., and Soto-Pedre E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg. Lasers Imaging 35 (2004) 350-351
9. Hida T., Chandler D., Arena J.E., and Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am. J. Ophthalmol. 101 (1986) 190-195
10. Jaissle G.B., Szurman P., and Bartz-Schmidt K.U. Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe 101 (2004) 121-128
11. Jonas J.B., Hayler J.K., and Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br. J. Ophthalmol. 84 (2000) 1064-1067
12. Jonas J.B., Kreissig I., Sofker A., and Degenring R.F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. 121 (2003) 57-61
13. Jonas J.B., Degenring R.F., Kreissig I., Friedemann T., and Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 19 (2005) 163-170
14. Jonas J.B. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 38 (2006) 218-245
15. Kong A.N., Yu R., Lei W., Mandlekar S., Tan T.H., and Ucker D.S. Differential activation of MAPK and ICE/ced-3 protease in chemical-induced apoptosis: the role of oxidative stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene expression and survivial or activation of caspases leading to apoptosis. Restor. Neurol. Neurosci. 12 (1998) 63-70
16. Machemer R., Sugita G., and Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans. Am. Ophthalmol. Soc. 77 (1979) 171-180
17. Nakamura T., Murata T., Hisatomi T., Enaida H., Sassa Y., Ueno A., Sakamoto T., and Ishibashi T. Ultrastructure of the vitreoretinal interface following the removal of the internal limiting membrane using indocyanine green. Curr. Eye. Res. 27 (2003) 395-399
18. Narayanan R., Mungcal J.K., Kenney M.C., Seigel G.M., and Kuppermann B.D. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 47 (2006) 722-728
19. Nishimura A., Kobayashi A., Segawa Y., Sakurai M., Shirao E., Shirao Y., and Sugiyama K. Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina 23 (2003) 777-779
20. Peyman G.A., Cheema R., Conway M.D., and Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloids during pars plana vitrectomy. Retina 20 (2000) 554-555
21. Rosenfeld P.J., Heier J.S., Hantsbarger G., and Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 632.e1
22. Satofuka S., Inoue M., Shinoda K., Ishida S., Imamura Y., and Ando Y. Adherence of intravitreally injected triamcinolone acetonide to the denuded retinal surface after internal limiting membrane peeling. Retina 25 (2005) 672-673
23. Schindler R.H., Chandler D., Thresher R., and Machemer R. The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol. 93 (1982) 415-417
24. Shaikh S., Ho S., Engelmann L.A., and Klemann S.W. Cell viability effects of triamcinolone acetonide and preservative vehicle formulations. Br. J. Ophthalmol. 90 (2006) 233-236
25. Spandau U.H.M., Derse M., Schmitz-Valckenberg P., Papoulis C., and Jonas J.B. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br. J. Ophthalmol. 89 (2005) 999-1003
26. Spitzer M.S., Wallenfels-Thilo B., Sierra A., Yoeruek E., Peters S., Henke-Fahle S., Bartz-Schmidt K.U., and Szurman P. Antiproliferative and cytotoxic properties of bevacizumab (Avastin) on different ocular cells. Br. J. Ophthalmol. 90 (2006) 1316-1321
27. Szurman P., Kaczmarek R., Spitzer M.S., Jaissle G.B., Decker P., Grisanti S., Henke-Fahle S., Aisenbrey S., and Bartz-Schmidt K.U. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp. Eye. Res. 83 (2006) 584-592
28. Szurman, P., Kaczmarek, R., Jaissle, G.B., Grisanti, S., Lüke, M., Spitzer, M.S., Heide, P.E., Bartz-Schmidt, K.U. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch. Clin. Exp. Ophthalmol., in press (Epub Sep 28).
29. Yeung C.K., Chan K.P., Chiang S.W.Y., Pang C.P., and Lam D.S.C. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest. Ophthalmol. Vis. Sci. 44 (2003) 5293-5300